Know what matters.
Before the readout.
Biotech traders: know the targets and red flags before each covered catalyst. Then see what met the bar, what missed, and what’s missing—measured against our original, locked research, with the source behind every number.
Below the bar. Source checked
Fictional study: the primary endpoint was met, but the 1.7-point improvement was 15% below the 2.0-point target published before the readout. Catalyst Intel compares results with fixed expectations and checks each number against its source.
- 26events committed
- 6bars hashed pre-readout
- 107on the radar, dates sourced
From an upcoming catalyst
to a clearer understanding.
A positive headline.
But a convincing result?
Drug trials and FDA decisions are full of nuance. An endpoint can be met while an important target is missed. A crucial detail can be absent from the release.
We write down what we will measure first. Then we do the comparison, with the evidence beside it.
Endpoint met.
1.7 MADRS points, against a bar of 2.0.
A Phase 3 in depression reads out, and the release says the primary endpoint was met. The bar, written from the comparator’s label before the readout, says how much it had to improve.
Quillon Therapeutics and QLN-217 are fictional; the format is real. Real research quotes the source sentence for every line of the bar and every reported number.
Expectations don’t move with the result.
What does QLN-217
have to show?
Significant on the MADRS.
Below the bar.
Quillon Therapeutics · QLN-217 · Phase 3, major depressive disorder
WHAT THIS TELLS YOU
Filings, registries, releases, labels.
Nothing a document does not say.
Documents in. Verdicts out.
Sources
- SEC EDGAR filings
- ClinicalTrials.gov records
- Company press releases
- FDA calendars and labels
- Market data
Catalyst Intel
The bar is written from the documents, hashed, and the print is measured against it.
Outputs
- Pre-event brief, before the readout
- Hashed bar, public
- Verdict, T+0
- Public ledger
Scouted, committed, hashed, measured.
Then opened to everyone.
One event, seven steps.
- Daily
Scouted
Filings scanned every morning; registries and the FDA calendar weekly.
- Slate
Committed
On the slate with its window. Exclusions listed with reasons.
- Before
Bar hashed
Written from documents, SHA-256 posted, brief sent.
- T+0
Readout
Numbers pulled from the release with their source sentences.
- Same day
Verdict
Measured against the frozen bar. Arithmetic, not opinion.
- After the call
Follow-up
Fuller data from the call or filing. Post-mortem recorded.
- +30 days
Public
Bar text and verdict open on the ledger for everyone.
Every bar and every verdict,
timestamped and never edited.
Scored in public.
-
$EVMN — EVO301
PARTIAL · Waiting for more data
Receipts -
$PCVX — VAX-31
PARTIAL · Waiting for more data
Receipts
Committed to next
- $IMCR — KIMMTRAK (tebentafusp) Subscribers first
- $MIRM — brelovitug Subscribers first
- $VSTM — VS-7375 Subscribers first
The full slate, the radar and what we excluded Every bar and verdict
A clear difference.
The same standard of evidence.
Free for the marquee events. $99 a month for the rest.
The public record
$0
- The marquee events, in full and on time
- Every bar's hash, before its readout
- Every other event, 30 days after it resolves
Subscription
$99/ month
Billed monthly. Cancel any time.
$990/ year
Twelve months for the price of ten. $82.50 a month.
- The pre-event brief before every readout, by email
- The verdict on the day, with source receipts
- Follow-ups as the call and the filings land
- Every event on the slate, not only the marquee ones
Subscriptions are not open yet. Leave your email and we will write when they open, with a link to sign up.
Subscribers get the bar before the readout and the verdict on the day, by email. The public site stays the same for everyone. A sealed event's bar text and verdict open on the ledger 30 days after it resolves. Not a recommendation service and not personalised advice. No positions in covered names, no money from covered companies. The full disclaimer · Subscription terms
Clarity starts
right here.
What is a bar?
The numeric threshold that states what a trial result has to reach to count as good. It is published before the readout and SHA-256 hashed, so it cannot be revised afterwards. Every line of it quotes a company document.
What is a verdict?
After the release, the numbers are extracted with their exact source sentences, checked against the document by plain code, and compared to the frozen bar. The outcome is one of BEAT, IN_LINE, THIN, MISS, SPIN, PARTIAL, NO_CALL or INSUFFICIENT_DISCLOSURE. The comparison is arithmetic against the bar; it is not a prediction of a stock move.
Where do the numbers come from?
SEC EDGAR filings, ClinicalTrials.gov registry records, company press releases, FDA calendars and labels, and end-of-day market data. Every line of a bar quotes one of these documents; a threshold no document states is left out.
What is free and what is paid?
The marquee events are published in full and on time. Every other event on the slate is sealed: its hash is public before the readout and the text and verdict open on the site 30 days later. Subscribers get the bar before the readout and the verdict on the day, by email.
How often will I receive research?
Publications follow the events on the slate rather than a daily schedule. The bar goes out ahead of a readout and the verdict lands the day the result prints. Dates can move, and a follow-up may arrive after the call or filing when fuller data is available.
Is this a prediction of what the stock will do?
No. The verdict measures the printed numbers against the frozen bar. It is not a forecast of returns, a measure of market consensus, or personalised advice. A result that clears the bar can still meet an unpredictable market reaction.